Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib StudyFunda Meric‐Bernstam, Shahneen Sandhu, Randy F. Sweis et al.|Clinical Cancer Research|2022Cited by 226
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.Funda Meric‐Bernstam, Jason J. Luke, Shahneen Sandhu et al.|Journal of Clinical Oncology|2019Cited by 192
Smoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization studyAbhinav Thakral, Osvaldo Espin‐Garcia, Jong Wook Lee et al.|Nature Communications|2024Cited by 42
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumorsErkut Borazanci, Josep Tabernero, Kimberly Hoffman et al.|ESMO Open|2022Cited by 37
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Michael Quigley, Chan Gao et al.|Unknown|2023Cited by 0